Claims
- 1. A method of treating a mammal having precancerous lesions comprising administering a pharmacologically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof:
- 2. The method of claim 1 wherein R0 represents hydrogen.
- 3. The method of claim 2 wherein R1 is selected from hydrogen, methyl, and iso-propyl.
- 4. The method of claim 3 wherein R3 represents hydrogen or methyl.
- 5. The method of claim 1 wherein said compound is selected from the group consisting of (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino [2′, 1′:6,1 lpyrdo[3,4-b]indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; (3S, 6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofiranyl)-3-methylpyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; (3S, 6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofiranyl)-2,3-dimethyl-pyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; and (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofiranyl)-2-isopropyl-pyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; and physiologically acceptable solvates thereof.
- 6. The method of claim 1 wherein said compound is selected from (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2′,1′:6,1]pyrido[3,4-b]indole-1,4-dione and physiologically acceptable solvates thereof.
- 7. A method for inhibiting the growth of neoplastic cells comprising exposing the cells to a growth inhibiting effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof:
- 8. The method of claim 7 wherein R0 represents hydrogen.
- 9. The method of claim 8 wherein R1 is selected from hydrogen, methyl, and iso-propyl.
- 10. The method of claim 9 wherein R3 represents hydrogen or methyl.
- 11. The method of claim 7 wherein said compound is selected from the group consisting of (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino [2′, 1′:6,1 lpyrido[3,4-b]indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; (3S, 6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3 -methylpyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; (3S, 6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2′,1′:6,1] pyrido [3,4-b]indole-1,4-dione; and (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2′, 1′:6,1] pyrido [3,4-b]indole-1,4-dione; and physiologically acceptable solvates thereof.
- 12. The method of claim 7 wherein said compound is selected from (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofiuranyl)-2-methyl-pyrazino[2′,1′:6,1]pyrido[3,4-b]indole-1,4-dione and physiologically acceptable solvates thereof.
- 13. A method for regulating apoptosis in human cells comprising exposing said cells to an effective amount of a compound of the formula:
- 14. The method of claim 13 wherein R0 represents hydrogen.
- 15. The method of claim 14 wherein R1 is selected from hydrogen, methyl, and iso-propyl.
- 16. The method of claim 15 wherein R3 represents hydrogen or methyl.
- 17. The method of claim 13 wherein said compound is selected from the group consisting of (6R, 12aR)-2,3,6,7,12,12a-hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino [2′, 1′:6,1 lpyrido[3,4-b]indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2′,1′:6,1] pyrido [3 ,4-b]indole-1,4-dione; (3S, 6R, 12aR)-2,3,6,7,12, 12a-Hexahydro-6-(5-benzofiranyl)-3-methylpyrazino[2 ′,1′:6,1] pyrido [3,4b]indole-1,4-dione; (3S, 6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2′,1′:6,1] pyrido [3,4-b]indole- 1,4-dione; and (6R, 1 2aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2′, 1′:6,1] pyrido [3,4-b]indole-1,4-dione; and physiologically acceptable solvates thereof.
- 18. The method of claim 13 wherein said compound is selected from (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2′,1′:6,1]pyrido[3,4-b]indole-1,4-dione and physiologically acceptable solvates thereof.
- 19. A method of treating a mammal having precancerous lesions comprising administering a pharmacologically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof:
- 20. The method according to claim 19 wherein said compounds are selected from the group consisting of cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3 ,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3 ,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo:b)furan-5-yl)-2-methylpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methylpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopropylethyl-6-(4-methoxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methy lpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido (3,4-b) indole-1,4-dione; (5aR, 12R, 14aS)-1,2,3,5,6,1,12,14a-octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo(1″,2″:4′,5′)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-5-1,4-dione; and physiologically acceptable salts and solvates thereof.
- 21. The method according to claim 20 wherein the compound is selected from (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; and physiologically acceptable salts and solvates thereof.
- 22. A method for inhibiting the growth of neoplastic cells comprising exposing the cells to a growth inhibiting effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof
- 23. The method accordimg to claim 22 wherein said compounds are selected from the group consisting of cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzocb)furan-5-yl)-2-methylpyralzino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methylpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopropylmethyl-6-(4-methoxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methy lpyrazino(2′,1′:6,1)pyrido(3,4-b)indole- 1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido (3,4-b) indole-1,4-dione; (5aR, 12R, 14aS)-1,2,3,5,6,1,12,14a-octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo(1″,2″:4′,5′)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-5-1,4-dione; and physiologically acceptable salts and solvates thereof.
- 24. The method according to claim 23 wherein the compound is selected from (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; and physiologically acceptable salts and solvates thereof.
- 25. A method for regulating apoptosis in human cells comprising exposing said cells to an effective amount of a compouind of formula:
- 26. The method according to claim 25 wherein said compounds are selected from the group consisting of cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzofb)furan-5-yl)-2-methylpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methylpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopropylnethyl-6-(4-methoxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methy lpyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; ( 6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido (3,4-b) indole-1,4-dione; (5aR, 12R, 14aS)-1,2,3,5,6,1,12,14a-octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo(1″,2″:4′,5′)pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-5-1,4-dione; and physiologically acceptable salts and solvates thereof.
- 27. The method according to claim 26 wherein the compound is selected from (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino(2′,1′:6,1)pyrido(3,4-b)indole-1,4-dione; and physiologically acceptable salts and solvates thereof.,
TECHNICAL FIELD
[0001] This invention relates to a method for the selective inhibition of neoplastic cells, for example, for the treatment or prevention of precancerous lesions or other neoplasias in mammals. This application is a Continuation of prior U.S. application Ser. No. 09/169,678, filed Oct. 9, 1998 entitled “Method of Inhibiting Neoplastic Cells with Tetracyclic Pyrido[3,4-B] Indole Derivatives” which is a Continuation-in-Part of U.S. patent application Ser. No. 09/007,098, filed Jan. 14, 1998 entitled “Method of Inhibiting Neoplastic Cells with Tetracyclic Pyrido[3,4-B] Indole Derivatives” both of which are incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09169678 |
Oct 1998 |
US |
Child |
09974271 |
Oct 2001 |
US |